[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355615-105":59,"doc-detail-355615-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","transcriptional-reinforcement-of-the-her2-ras-network-in-her2-positive-gastric-cancer-the-runx-sos1-axis-in-context","Transcriptional Reinforcement of the HER2–RAS Network in HER2-Positive Gastric Cancer: The RUNX–SOS1 Axis in Context","","HER2-positive gastric cancer is a molecular subtype marked by chromosomal instability, variable HER2 amplification, and extensive intratumoral heterogeneity. While HER2-targeted treatments improve outcomes, resistance often emerges, limiting durable benefit. Resistance involves bypass signaling via alternative receptor tyrosine kinases, pathway reactivation including PI3K–AKT and MAPK, and dynamic HER2-expression changes during therapy. This review focuses on transcriptional reinforcement within the HER2–RAS network, emphasizing RUNX-dependent regulation of SOS1 as a downstream mechanism supporting persistent oncogenic signaling. It contextualizes this axis within established and emerging therapeutic strategies.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/transcriptional-reinforcement-of-the-her2-ras-network-in-her2-positive-gastric-cancer-the-runx-sos1-axis-in-context/355615/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/transcriptional-reinforcement-of-the-her2-ras-network-in-her2-positive-gastric-cancer-the-runx-sos1-axis-in-context/355615.png","ImageObject",300,407,{"name":92,"@type":93},"วิน","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why does HER2-targeted therapy often fail in HER2-positive gastric cancer?","Question",{"text":113,"@type":114},"Resistance commonly arises from bypass signaling through alternative receptor tyrosine kinases, reactivation of downstream pathways such as PI3K–AKT and MAPK, and changes in HER2 expression over time.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What role does SOS1 play in HER2-driven signaling?",{"text":118,"@type":114},"Upon HER2 activation, adaptor proteins recruit SOS1 to the plasma membrane, where SOS1 promotes GDP–GTP exchange on RAS and initiates downstream kinase activation, shaping MAPK signaling magnitude and duration.",{"name":120,"@type":111,"acceptedAnswer":121},"How does transcriptional reinforcement relate to the HER2–RAS network?",{"text":122,"@type":114},"The review describes transcriptional reinforcement as a mechanism that sustains oncogenic signaling by regulating components downstream of receptor inhibition. It highlights RUNX-dependent regulation of SOS1 as a potential driver of persistent pathway activity.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},355615,1790257339,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},2336475104736,"https://ap-avatar.wpscdn.com/avatar/22000c4c5e0e5b17e70?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786591360781797222","Cancer Science  \nTranscriptional Reinforcement of the HER2–RAS Network in HER2-Positive Gastric Cancer: The RUNX–SOS1 Axis in Context  \nTatsuya Masuda1,2 | Takayoshi Watanabe1 | Toshinori Ozaki1 | Yasuhiko Kamikubo1,2  \n1Division of Molecular Carcinogenesis, Chiba Cancer Center Research Institute, Chiba, Japan | 2Department of Human Health Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan  \nCorrespondence: Yasuhiko Kamikubo ([ykamikubo@chiba-cc.jp](ykamikubo@chiba-cc.jp))  \nReceived: 8 January 2026 | Revised: 24 February 2026 | Accepted: 1 March 2026  \nKeywords: gastric cancer | HER2 | pyrrole–imidazole polyamides | RUNX transcription factors | SOS1 | transcriptional reinforcement  \nABSTRACT  \nHER2-positive gastric cancer represents a distinct molecular subtype characterized by chromosomal instability, variable HER2 amplification, and substantial intratumoral heterogeneity. Although HER2-targeted therapies have improved clinical outcomes, therapeutic resistance commonly develops and limits long-term benefit. Established resistance mechanisms include bypass signaling through alternative receptor tyrosine kinases, reactivation of downstream pathways such as PI3K–AKT and MAPK, and dynamic changes in HER2 expression during treatment. These findings underscore the complexity of signaling regulation in HER2-driven tumors and indicate that mechanisms beyond receptor-level inhibition contribute to persistent oncogenic signaling. In this review, we examine the concept of transcriptional reinforcement within the HER2–RAS signaling network and discuss RUNX-dependent regulation of SOS1 as a downstream mechanism that may sustain signaling activity. We position this regulatory axis within the broader landscape of established resistance mechanisms and emerging therapeutic strategies, including antibody–drug conjugates, kinase inhibitors, and rational combination approaches. By integrating canonical resistance pathways with transcriptional regulation, this review provides a balanced perspective on how downstream regulatory processes may influence therapeutic response in HER2-positive gastric cancer.  \n1 | Introduction  \nGastric cancer (GC) remains one of the leading causes of cancerrelated mortality worldwide, despite gradual improvements in diagnostic methods and systemic therapies. Molecular classification has identified several biologically distinct subtypes, among which human epidermal growth factor receptor 2–positive gastric cancer (HER2-positive GC) accounts for approximately 15%–20% of cases and is defined by amplification or overexpression of the ERBB2 gene encoding human epidermal  \ngrowth factor receptor 2 (HER2) [1–3]. The landmark ToGA trial established trastuzumab in combination with chemotherapy as the first effective HER2-targeted therapy for this subgroup, demonstrating a statistically significant but limited improvement in overall survival compared with chemotherapy alone [1] . This study provided clinical evidence that HER2 can function asan oncogenic driver in GC.  \nHowever, in contrast to HER2-positive breast cancer, the benefit of HER2-targeted therapy in GC is often limited by intrinsic  \n\n| Abbreviations: ERBB2, Erb-B2 receptor tyrosine kinase 2; HER2, human epidermal growth factor receptor 2; MAPK, mitogen-activated protein kinase; PI, pyrrole–imidazole; RAS, rat sarcoma viral oncogene homolog; RUNX, runt-related transcription factor; SOS1, Son of Sevenless homolog 1.\u003Cbr>Tatsuya Masuda and Takayoshi Watanabe contributed equally to this work. |\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.\u003Cbr>© 2026 The Author(s). Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. |\n\nCancer Science, 2026; 117:1235–1243 1235  \n[https://doi.org/10.111","cbCaintn25ux6gUi","https://ap.wps.com/l/cbCaintn25ux6gUi","pdf",902460,"English","# Introduction\n## HER2-positive gastric cancer and resistance mechanisms\n## HER2-driven MAPK signaling and SOS1 function\n## Transcriptional reinforcement and RUNX–SOS1 axis\n## Therapeutic context","[{\"question\":\"Why does HER2-targeted therapy often fail in HER2-positive gastric cancer?\",\"answer\":\"Resistance commonly arises from bypass signaling through alternative receptor tyrosine kinases, reactivation of downstream pathways such as PI3K–AKT and MAPK, and changes in HER2 expression over time.\"},{\"question\":\"What role does SOS1 play in HER2-driven signaling?\",\"answer\":\"Upon HER2 activation, adaptor proteins recruit SOS1 to the plasma membrane, where SOS1 promotes GDP–GTP exchange on RAS and initiates downstream kinase activation, shaping MAPK signaling magnitude and duration.\"},{\"question\":\"How does transcriptional reinforcement relate to the HER2–RAS network?\",\"answer\":\"The review describes transcriptional reinforcement as a mechanism that sustains oncogenic signaling by regulating components downstream of receptor inhibition. It highlights RUNX-dependent regulation of SOS1 as a potential driver of persistent pathway activity.\"}]","Transcriptional Reinforcement of the HER2–RAS Network in HER2-Positive Gastric Cancer: The RUNX–SOS1 Axis in Context | PDF",1790120159,23,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/89235064e4c6dc279fcc88d019362039.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/208b315f66733883eaf2932caf9b91a0.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d90f0183a25d1458f0e3d2b2eb1f9762.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4b96644df6c0da29de170785025c8b67.webp",980,1287]